Presenters
Scientific Director
Prof. Thomas Unger, MD, PhD, FESC, FAHA
Course Details
Atrial fibrillation is an important cause of preventable thromboembolic stroke. In this webinar, Professor Thomas Unger (Maastricht University, the Netherlands) discusses the pathogenesis of atrial fibrillation and the role of the renin-angiotensin system. He then shared clinical evidence on the benefits of anticoagulation on the prevention of thromboembolic stroke in atrial fibrillation, as well as the evidence base supporting non-vitamin K oral anticoagulants. Lastly, he discussed specific clinical aspects on the use of dabigatran as the first non-vitamin K oral anticoagulant for stroke prevention in atrial fibrillation.
Estimated time of Completion: 22 mins.
CPD Points: 1 Point
PRC Program No: PROG-2023-59765
Hypertension and Atrial Fibrillation: A Conundrum? Course Outline
- Atrial Fibrillation: A serious condition
- Blood Pressure and Risk of AF: Mendelian Randomization Study
- Blood Pressure Control and AF
- RAS in cardiovascular pathology
- Temisartan vs Amlodipine and Ramipril in Recurrent AF
- Effect of Telmisartan on AF in Patients with Hypertension: A Systematic Review and Meta-analysis
- Strategy in Hypertensive Patients with Suspected AF
- NOACS: New Direct Oral Anticoagulants = DOACS: Direct Oral Coagulants
- Dabigatran versus Warfarin
- GLORIA Registry: Phase III Dabigatran vs VKAs
- Idarucizumab
PC-PH-104960 / July 2023